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Meningitis, meningoencephalitis and sepsis are severe diseases causing many deaths all over 
the world every year. Escherichia coli (E. coli) is the most common Gram-negative bacterium 
causing neonatal meningitis and sepsis but also causes meningitis in old and 
immunocompromised people. Especially immunocompromised patients carry a high risk of 
developing infections e.g. in the central nervous system (CNS) caused by different pathogens, 
such as bacteria, viruses and fungi. One cause of this increased susceptibility to CNS 
infections might be a decreased local immune defense. Microglial cells, the resident immune 
cells of the brain, constitutively express Toll-like receptors (TLRs) and nucleotide-binding 
oligomerization domain (NOD)-like receptors, which are known to trigger innate immune 
responses against microbial infection upon pathogen recognition.  
This study aimed at three major questions: to detect whether stimulation of microglial cells 
with (i) the Nod2 ligand muramyl dipeptide (MDP) or (ii) the viral TLR3 agonist poly(I:C) 
affects phagocytosis and intracellular killing of E. coli K1, and (iii) to detect if there is 
synergism between MDP and the tested TLR agonists on the mentioned parameters. 
Therefore, primary cultures of murine microglia were stimulated with MDP or a TLR agonist 
alone as well as in combinations. Phagocytic activity was determined after 30 and 90 min of 
incubation with E. coli K1. To analyze the ability of microglia to kill ingested E. coli, bacteria 
were quantified at different time points after phagocytosis.  
In the current work, I was able to demonstrate for the first time that MDP and poly(I:C) alone 
increased phagocytosis and intracellular killing of E. coli K1 in murine microglia. In 
comparison, activation through the TLR system caused a stronger increase of phagocytosis 
than stimulation of the Nod2 system alone. Most notably, upon co-stimulation, the Nod2 and 
TLR systems can synergize to enhance both the phagocytic and bactericidal activities of 
microglial cells.  
In conclusion, microglial innate immune responses to invading E. coli K1 are enhanced by 
stimulation with the TLR3 agonist and Nod2 receptor alone as well as by a dual stimulation 
with poly(I:C) and MDP. These findings underline the cooperative action of innate immune 
receptor/signalling systems in fighting infectious threats. These results indicate that more 
studies should be investigated to find out whether a pre-stimulation with a Nod2 receptor 




immunocompromised patients and could therefore help the patients to develop mechanisms of 
resistance against lethal pathogens.  
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1.1 The immune system and the special role of microglia  
The human body is a complex network of multiple interacting organ systems. Each of these 
has a different function to maintain balance in the individual. The immune system for 
example plays a pivotal role in protecting the organism from invading pathogens, such as 
bacteria, fungi, viruses and parasites. Immunity in higher vertebrates can be subdivided into 
two main parts, the innate and the adaptive arms, both of which offering inducible responses 
and interacting with each other (Beutler 2000). While adaptive immunity acts specifically 
against pathogens and has an immunological memory, innate immunity interacts non-
specifically but within minutes to few hours upon pathogen encounter thus providing the 
host’s first line of defence. Together with anatomical and humoral barriers, cellular barriers 
belong to this system and play the most important role in innate immunity in case of 
inflammation.  
In particular, the central nervous system (CNS) needs specific mechanisms of defence as “the 
neurons of the central nervous system cannot divide and be replenished, and therefore need to 
be protected against pathogens” (Ransohoff and Cardona 2010; p. 253). A part of this 
challenge is taken over by microglial cells, which play a special role in the CNS. Besides their 
immune regulatory function, microglia support communication among astrocytes (Giaume 
2010), which maintain homeostasis in the brain. Microglia are the resident innate immune 
cells of the CNS. They act as first active defence against microorganisms in the brain tissue 
(Kreutzberg 1995, Mariani and Kielian 2009) and therefore have been of greatest interest for 
research during the last decades. In the healthy adult CNS, resting microglia constantly scan 
their environment with highly motile processes (Nimmerjahn et al. 2005). Upon detection of 
any disturbance of CNS homeostasis, microglia can undergo from the 'resting' to an alerted or 
'activated' state (Hanisch and Kettelman 2007). As specialist macrophages, activated 
microglia can phagocytose and kill pathogens invading the CNS. Once the pathogen is 
engulfed, it is incorporated and digested in phagosomes that mature by increasing 
acidification upon fusion with endosomes and later with lysosomes. Amoeboid microglial 
cells from neonatal rats have been shown to efficiently internalise a non-pathogenic E. coli 
strain in phagosomes one day after a single intracerebral injection (Kaur et al. 2004). In the 
phagolysosome, E. coli is exposed to reactive oxygen species and other hydrolytic enzymes 
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which eventually results in bacterial lysis. To accomplish pathogen clearance, microglia 
express pattern-recognition receptors (PRRs) such as the different members of the Toll-like 
receptor (TLR) family (Akira et al. 2006, Kielian 2006, Hanisch and Kettenmann 2007, 
Mariani and Kielian 2009) and the nucleotide-binding oligomerization domain (Nod)-like 
receptors (Sterka and Marriott 2006). PRRs are able to sense a variety of highly conserved 
structural motifs expressed by microbial pathogens, called pathogen-associated molecular 
patterns (PAMPs). Upon PAMP recognition, microglia mediate and induce immune responses 
by releasing chemokines and cytokines (Olson and Miller 2004, Sterka and Marriott 2006), 
such as tumor necrosis factor-α (TNF-α), chemokine C-X-C motif ligand 1 (CXCL1) and 
interleukin-6 (IL-6) as well as free radicals leading to further activations of the immune 
system (Hanisch et al. 2002). Recent studies showed that the activation of murine microglia 
by ligands of TLR1/2, TLR4 and TLR9 can increase bacterial uptake as well as intracellular 
killing of Gram-negative and Gram-positive bacteria (Ribes et al. 2009). 
Microglial cells also express Nod-like receptors such as Nod1 and Nod2 (Sterka and Marriott 
2006). NOD2 and its ligand, muramyl dipeptide (MDP), are known to trigger innate immune 
responses against microbial infection upon pathogen recognition (Inohara and Nunez 2003). 
Furthermore, it has been described that Nod2 expression is upregulated when cells are 
exposed to TLR or MDP and the production of chemo- and cytokines is enhanced (Sterka and 
Marriott 2006). However, so far there is no evidence that stimulation of the Nod2 system 
contributes to the elimination of E. coli K1 by microglial cells. 
1.1.1 Chemo- and Cytokines 
The variety and complex functions of chemo- and cytokines will be briefly discussed at this 
point. Chemo- and cytokines, such as TNF-α, CXCL1 and IL-6 are released by various cell 
types, hereunder stimulated microglia, and act as transmitters mediating immune responses 
(Cavaillon 1994, Hanisch 2002, Sterka and Marriott 2006). Microglia can “communicate” and 
regulate the release of cytokines by themselves (Cavaillon 1994), whereupon the balance of 
different cytokines seems to be essential for the outcome in case of infection (Hopkins and 
Rothwell 1995, Rodriguez-Gaspar et al. 2001). Among cytokines, TNF-α plays a central role 
in the control of local and systemic infection. A neuroprotective effect is described at low 
concentrations whereas in contrast, an overproduction can cause multiorgan failure, fever, 
hypotension and tissue damage (Carlson et al. 1999, Hanisch 2002). The same effects are 
described for IL-6 (Carlson et al. 1999), which has among its great variety of functions, a pro-
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inflammatory and an anti-inflammatory effect and is important in mediating fever and acute-
phase reactions (Helle et al. 1988).  
Chemokines (a shortening of chemoattractant cytokines) induce chemotaxis, i.e. they activate 
cells to migrate to inflammatory sites. They can be divided into four groups depending on 
their chemical structure or can also be classified according to their function into inflammatory 
and homeostatic chemokines. An example of a (pro-) inflammatory chemokine is CXCL1 
(also known as KC or Gro-α), which has neutrophil chemoattractant activity and plays a 
central role in inflammatory processes (Hanisch 2002). 
1.2 Toll - like receptors (TLRs) 
In 1985, Christiane Nüsslein-Vollhard discovered a gene responsible for the appearance of the 
small fruit fly, called Drosophila, to look different or weird. She was so enthusiastic about her 
discovery that she used the German vocabulary for awesome, which is “toll” to name the gene 
(Hannson and Edfeldt 2005). Nearly ten years later, Lemaitre et al. (1996) discovered that the 
gene was not only responsible for a different phenotype but also played a role in the immunity 
of Drosophila. One year later, Medzhitov et al. (1997) were able to clone a human homologue 
to the Toll receptor, a Toll-like receptor, and reported its ability to activate adaptive 
immunity. Until today this discovery has encouraged many research groups to perform further 
investigations to gather more information.  
It is known that TLRs are transmembrane proteins playing a central role in innate immunity 
and belong to PRRs, able to detect highly conserved pathogen structures (PAMPs) which are 
essential for the survival of pathogens (Takeuchi et al. 2002). On the other hand, the TLR 
system can also be stimulated by the non-physiological appearance, altered structure or 
unusual concentration of certain endogenous molecules, which are produced and released by 
damaged cells. So far there have been identified 10 members of the TLR family in humans 
and 12 in mice (Takeuchi et al. 2002, Kawai and Akira 2011). TLRs are expressed on 
antigen-presenting cells such as dendritic cells, macrophages or microglia (Visintin et al. 
2001, Kielian 2006). In the present study, TLR1/2, TLR3, TLR4 and TLR9 of microglial cells 
were stimulated with known TLR agonists (see below). 
TLR1, TLR2 and TLR4 are located on the cell surface. TLR1 and TLR2 cooperate through 
their cytoplasmic domain to form a heterodimer enabling the cell to detect e.g. Gram-negative 
bacteria, lipoteichoic acids from Gram-positive bacteria and Mycoplasma (Takeda et al. 
2003). TLR4 is a dimer that responds to bacterial lipopolysaccharide (LPS), a component of 
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the outer membrane of Gram-negative bacteria (Akira et al. 2006). In contrast, TLR3 and 
TLR9 are located in intracellular compartments such as endosome/endoplasmatic reticulum 
membranes (Kato et al. 2008, p. 1601). While TLR3 responds to double-stranded RNA 
(dsRNA) (Alexopoulou et al. 2001), TLR9 recognizes bacterial DNA containing CpG motifs 
(Hemmi et al. 2000). 
Once the pathogen is detected the information has to be translated to induce further activation 
of the immune system (Ozinsky et al. 2000, Takeuchi et al. 2002). Upon recognition of 
pathogens, TLR can induce responses through a variety of signal cascades. Myeloid 
differentiation protein 88 (MyD88) is an adaptor protein of interleukin-1 receptor associated 
kinase (IRAK) that leads to the activation of nuclear factor κB (Medzhitov and Janeway 2000, 
Akira et al. 2006, Carpenter and O´Neill 2007). All TLR except for TLR3 mediate responses 
through MyD88 (Yamamato et al. 2004).  TLR3 depends on Toll/interleukin-1 receptor 
domain-containing adapter inducing IFN-β (TRIF) and melanoma-differentiation-associated 
gene 5 (MDA5), which seem to play a central role in immune defense in case of viral 
infections (Alexopoulou et al. 2001, Kato et al. 2006, Town et al. 2006). TLR4 mediation 
needs adaptor molecule MyD88 and TRIF signaling pathways (Kawai et al. 1999; Yamamato 
et al. 2004). 
1.3 Nucleotide-binding oligomerization domain like (NOD) receptors  
In recent years, NOD proteins are gaining interest since NOD2, also designated Caspase 
Recruitment Domain 15 (CARD15), receptor mutations have been identified in patients 
suffering from Crohn’s disease (Hugot et al. 2001). Nod2 is a member of the CED4/APAF1 
family of apoptosis regulators (Ogura et al. 2001) which can recognize peptidoglycan (PGN)-
derived fragments, including the minimal bioactive PG motif common to all bacteria, i.e. 
MDP which is also used as a NOD2 synthetic ligand (Girardin et al. 2003). By an activation 
of the serine/threonine kinase RICK (receptor-interacting serine/threonine kinase; also known 
as RIP2), MDP triggers the production of pro-inflammatory mediators through NF-κB 
signalling (Ogura et al. 2001, Strober et al. 2006). NOD proteins have been identified in 
immune and non-immune cell types (Strober et al. 2006, Ting and Davis 2005). Sterka and 
Marriott (2006) showed that the expression of Nod2 receptors and the downstream effector 
molecule Rip2 in microglial cells are increased by stimulation with MDP and agonists of 
TLR4 and TLR5.  
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1.4 Characterisation of the receptor ligands 
1.4.1 TLR agonists 
To stimulate the TLR system of microglial cells, three well-tested ligands, known to enhance 
phagocytosis and intracellular killing of bacteria (Ribes et al. 2009), as well as one viral 
agonist, were used. I will briefly introduce these stimuli in the following sections. 
1.4.1.1 The TLR1/2 agonist Pam3CSK4 
Pam3CSK4 is a synthetic tripalmitoylated lipopeptide that imitates a virulent factor occurring 
on bacteria. When the human body is challenged with E. coli the expression of TLR2 is 
upregulated on monocytes, although it does not correlate with the amount of bacteria (Beran 
et al. 2011). 
1.4.1.2 The viral TLR3 agonist poly(I:C) 
Polyinosine–polycytidylic acid [poly(I:C)], a synthetic double-stranded RNA analogue, was 
used as a viral stimulant of the immune system. Poly(I:C) stimulates immunity through 
different receptors. At first, poly(I:C) was thought to act as specific TLR3 ligand through its 
associated adaptor protein TRIF in macrophages, dendritic cells and microglia (Alexopoulou 
et al. 2001, Town et al. 2006). Recently, Kato and collaborators have identified MDA5 as 
another mechanism how microglial cells can recognize the presence of viral dsRNA (Kato et 
al. 2006). MDA5 is not only able to recognize poly(I:C), but also plays a central role in the 
immune system since MDA5 deficient (MDA5-/-) mice are more susceptible to viral 
infections. In response to poly(I:C), MDA5-/- mice did not produce IFN-alpha and IFN-beta, 
and showed impaired production of IL-6 and IL-12p40 which indicates that TLR3 is not the 
only receptor poly(I:C) binds to (Kato et al. 2006). Despite these findings, poly(I:C) behaved 
in this work as a suitable TLR3 agonist as it has been reported to be more selective than 
alternative compounds, such as poly(A:U) (Hanisch et al., unpublished observations). 
1.4.1.3 The TLR4 agonist LPS 
For an activation of TLR4, microglial cells were exposed to LPS from E. coli serotype 
026:B6. LPS consists of chains of sugar, called polysaccharides, and fatty components and is 
found in the extern all part of the cell membrane contributing to the structural and functional 
membrane integrity of Gram-negative bacteria (Silhavy et al. 2010, Wang and Quinn 2010). 
Upon bacterial lysis, these parts of the membrane are released and then called endotoxins 
(Akira et al. 2006).  
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In case of a systemic infection, LPS is able to reach the brain directly fixed on LPS binding 
protein. This complex ligates to a special co-receptor of TLR4, its prototypic associate 
glycosylphosphatidylinositol-anchored cluster of differentiation (CD) 14, placed on the 
surface of microglial cells (Poltorak 1998, Akira et al. 2006). The interaction of LPS with 
CD14 leads to the recruiting of intracellular MyD88, an adaptor protein of IRAK  leading to 
an activation of a cascade of immune reactions (Medzhitov and Janeway 2000, Akira et al. 
2006, Carpenter and O´Neill 2007). There are also findings indicating that TLR4 additionally 
needs MD-2 to form a complex to detect LPS (Shimazu et al. 1999). 
1.4.1.4 The TLR9 agonist CpG 
Cytosine-phosphate-guanosine (CpG) is a part of the DNA from different organisms. While 
viral and bacterial DNA contain a high proportion of unmethylated CpG dinucleotides, 
mammalian DNA has less and mostly methylated CpG (Hemmi et al. 2000). These 
differences concerning the structure of CpG in the DNA are detected by TLR9 and enable the 
immune system to distinguish foreign DNA from self-DNA. Underlining this thesis, Hemmi 
et al. (2000) showed that wild-type dendritic cells express more CD40, CD80, CD86 and 
major histocompatibility complex (MHC) class II after exposure to CpG than TLR9-deficient 
cells. This indicates that TLR9 is essential to detect CpG (Hemmi et al. 2000). Today, 
synthetic unmethylated CpG is used as a PAMP to simulate invading pathogens and induce an 
immune reaction. Clinical research with CpG focuses on e.g. improving vaccination using it 
as an immunoadjuvant (Rothenfußer et al. 2001). 
1.4.2 The NOD2 receptor agonist MDP 
N-Acetylmuramyl-L-Alanyl-D-Isoglutamine also known as MDP is “the minimal bioactive 
peptidoglycan motif common to all bacteria” (Girardin et al. 2003, p. 8869) that can be 
recognized by NOD2, inducing different signal cascades. MDP derivatives enhanced 
phagocytic and microbicidal activities of monocytes and macrophages (Cummings et al. 
1980). In human dendritic cells, MDP treatment augmented the expression of major 
histocompatibility complex class II (MHC class II) antigens (Cooney et al. 2010) and resulted 
in a weak but consistent up-regulation of CD80 and CD86 (Kramer et al. 2006). The essential 
structure of MDP has been used as an adjuvant component in vaccines (Chedid 1983).  
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1.5 Characterisation and pathogenicity of Escherichia coli 
E. coli is a rod-shaped Gram-negative bacterium which belongs to the Enterobacteriacea 
family. Although it is part of the human gut flora, E. coli can cause inflammation when 
invading other organ systems. Besides infections which often can be treated without sequela 
(e.g. infections of the urinary tract), E. coli is the leading cause of Gram-negative neonatal 
bacterial sepsis and meningitis with a high associated fatality rate and permanent neurological 
dysfunction in more than half of the survivors (Dawson et al. 1999, Mittal et al. 2011). E. coli 
also causes meningitis in older (Cabellos et al. 2009) and immunocompromised patients 
(Roos 2009). To determine which type of E. coli was most commonly causing meningitis, 
cerebrospinal fluid (CSF) of infants with meningitis caused by E. coil- were studied. In 
approximately 

80% of these E. coli strains the polysaccharide capsule K1 was present 
(McCracken et al. 1974). Later it has been shown that the presence of this capsule allows E. 
coli strains to survive in the bloodstream and ultimately to cross the blood-brain barrier by 
penetrating the brain’s micro-vascular endothelial cell layer and entering the CNS (Kim 2002) 
which makes it highly virulent.  
1.6 Meningitis 
The brain and the spinal cord are surrounded by layers of connective tissue with a protective 
and metabolic function, the so-called meninges. The inflammation of these layers is defined 
as meningitis, which can be lethal. Meningitis can be induced by infection with bacteria, 
viruses or other microorganisms. Clinically, patients suffer from headache, high sensitivity to 
light, stiffness of the neck, hyperesthesia, fever, nausea, vomiting and confusion (van de Beek 
et al. 2004). As complications, encephalitis and sepsis with lethal outcomes are possible. Until 
nowadays, meningitis is a severe disease causing thousands of victims all over the world even 
in countries with high medical standards and diverse schemes of antibiotic treatments 
(Hoffmann and Weber 2009). Especially immunocompromised patients such as prematurely 
born infants and elderly carry a high risk of developing CNS infections including E. coli 
meningitis and meningoencephalitis (Teng et al. 2004, Roos 2009). One cause of this 
increased susceptibility to CNS infections might be a decreased local immune defence. 
However, even people with an intact immune system can suffer or even die of the 
consequences of meningitis, e.g. septic shock or brain oedema, in particular, when the therapy 
is not immediately started (Pfister et al. 1993, Proulx et al. 2005).  
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1.7 Outline  
Infections with E. coli K1 can lead to serious diseases like sepsis, meningitis or 
meningoencephalitis which are often lethal, especially in immunocompromised patients. 
Therefore, many studies aimed to strengthen the immune system and its ways to 
communicate. Many studies have focused on bacterial TLR agonists and their effect on 
microglial cells but there are no reports about the effect of the viral TLR3 agonist poly(I:C) 
on the phagocytic activity of microglia. 
In addition to TLRs, microglia express different kind of receptors, such as NOD receptors. So 
far it is known that mutations of NOD2 receptor are associated with chronic inflammatory 
bowel diseases such as Crohn´s disease. The question whether infections of the brain correlate 
with abnormalities this receptor is a matter of interest. We do not know whether activation of 
NOD receptor increases microglial response in case of infection. Therefore following 
questions should be addressed. 
 
Does stimulation of murine microglial cells with  
1. MDP alone 
2. Poly(I:C) alone 




a) Cytokine and chemokine release? 
b) Phagocytosis of E. coli K1? 
c) Intracellular killing of E. coli K1? 
 
The aim of this study was to investigate whether the single stimulation of microglial cells 
with the agonist of the Nod2 receptor (MDP) or the TLR3 [poly(I:C)] have an effect on 
chemo-/cytokine production and phagocytosis and intracellular killing of E. coli K1. In a 
second set of experiments it was tested whether co-stimulation of MDP with TLR1/2, TLR3, 
TLR4 or TLR9 agonists influence the previously mentioned parameters.  
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2 Material and Methods  
2.1 Description of the study  
In the present study, primary microglial cell cultures from mice aged one to three days were 
stimulated with agonists of the Nod and TLR systems alone or in combination. The aim was 
to investigate whether a stimulation of microglial cells with MDP or poly(I:C) alone or the 
co-stimulation of MDP and different TLR agonists [Pam3CSK4, poly (I:C), LPS and CpG] 
increases chemo- and cytokine release and enables microglial cells to phagocytose and 
eliminate higher amounts of ingested bacteria in comparison to unstimulated cells. This could 
improve CNS resistance to infections and therefore especially have impact in 
immunocompromised patients. 
2.2 Materials 
Chemicals were used from BioLegend (San Diego, USA), Braun (Melsungen, Germany), 
Eppendorf (Hamburg, Germany), Greiner bio-one (Solingen, Germany), Invitrogen 
(Karlsruhe, Germany), InvivoGen (San Diego, USA), Merck (Darmstadt, Germany), R&D-
Systems (Wiesbaden, Germany), Roche (Mannheim, Germany), Sarstedt (Nümbrecht, 
Germany), Sigma-Aldrich Biochemistry (Saint Louis, USA), Thermo Scientific, TECAN 
(Crailsheim, Germany). They were purchased in commercially available form. 
2.2.1 Chemicals  
Acetic acid (100%)    Merck, Darmstadt, Germany  
Cell Proliferation Reagent WST-1 Cat.No. 11 644 807 001, Roche, Mannheim, 
Germany 
Cytochalasin D (CD)    Sigma-Aldrich, St. Louis, USA   
Cytosine-phosphate-guanosine (CpG)  CpG oligodesoxynucleotide 1668 (TCC ATG 
ACG TTC ATG   CT; 6,383 Da; TIB Molbiol, 
Berlin, Germany) 
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Chemokine (C-X-C motif) ligand 1              
(CXCL1)      DuoSet ELISA Development Kit  R&D Systems, 
      Wiesbaden, Germany 
Dulbecco’s Modified Eagle Medium                 
DMEM + GlutaMAX –I   Gibco, Karlsruhe, Germany  
DuoSet ELISA Development Kits   R&D Systems, Wiesbaden, Germany 
Escherichia coli K1 (E. coli K1) gift of Dr. G. Zysk, Institute of Medical 
Microbiology and     Virology, Heinrich-Heine-
University, Düsseldorf, Germany 
Ethyl alcohol     Merck, Darmstadt, Germany 
Foetal bovine serum (FBS)   Gibco, Karlsruhe, Germany  
Gentamicin      Sigma-Aldrich, St. Louis, USA 
Interleucin-6 (IL-6) DuoSet ELISA                   
Development Kit    R&D Systems, Wiesbaden, Germany 
Lipopolysaccharide (LPS): Escherichia coli                
serotype 026:B6    Sigma-Aldrich, St. Louis, USA      
Muramyl dipetide (MDP)   InvivoGen, San Diego, USA 
Naphthyl-ethylendiamin Dihydrochlorid                  
(NED)      Sigma-Aldrich, St. Louis, USA  
Pam3CSK4 (910.5 Da)   EMC Microcollections, Tübingen, Germany 
Penicillin – Streptomycin   Gibco, Karlsruhe, Germany 
Phosphate-buffered saline (PBS):  Invitrogen, New York, USA 
Polyinosine–polycytidylic acid            
[Poly(I:C)] (

1.5 8kb)   InvivoGen, San Diego, USA 
Sterile saline      Braun, Melsungen, Germany 
Sulfonamid     Sigma-Aldrich, St. Louis, USA 
Tumor necrosis factor α (TNF-a) DuoSet                  
ELISA Development Kit     BioLegend San Diego, USA  
Trypan blue      Sigma, St. Louis, USA 
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2.2.2 Equipment and software 
Blood agar plates  Microbiology, University of medicine, Göttingen, 
Germany 
Centrifuge     Eppendorf, Hamburg, Germany 
Coverslips      Menzel, Braunschweig, Germany 
Eppendorf cups     Eppendorf, Hamburg, Germany 
Extractor hood    Heraeus, Thermo Scientific 
Falcon tubes, 

15ml  and 

50ml   Sarstedt, Nümbrecht, Germany 
Genios multiplate reader    Tecan, Crailsheim, Germany 
GraphPad Prism 4.0 Software   GraphPad, San Diego, USA 
Incubator     Thermo Scientific, Braunschweig, Germany 
Microscope (magnification: 40 x):   Olympus, Hamburg, Germany 
Neubauer Counting Chamber  LO-Laboroptik, Bad Homburg, Germany 
Petri dishes      Greiner bio-one, Solingen, Germany 
Pipettes      Eppendorf, Hamburg, Germany 
Pipette tips     Eppendorf, Hamburg, Germany 
T75 culture flask    Corning Costar, Wiesbaden, Germany 
Vortexer      Heidolph REAX top, Schwabach, Germany 
Waterbath      GFL, Burgwedel, Germany 
24- and 96-well-plates    Greiner bio-one, Solingen, Germany 
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2.3 Primary mouse microglial cell cultures 
2.3.1  Preparation of mouse brains 
In advance 70% alcohol was prepared by mixing 700 ml of 99% ethyl alcohol with 300 ml 
distilled water. To prepare phosphate-buffered saline (PBS), 23,875 g of PBS Dulbecco-
powder was mixed with 2.5 l distilled water and mixed by using magnet-rotors. Thereafter the 
solution was autoclaved. Mixed cultures of astrocytes and microglial cells were prepared as 
previously described by Ebert et al. (2005). Brains of wild type newborn C57Bl/6 mice, aged 
one to three days, were used to prepare primary cultures of microglial cells. Mice were killed 
by decapitation and disinfected with 70% alcohol. The brains were put into a petri dish with 
iced PBS. Meninges and blood vessels were removed under the microscope with the help of 
forceps. All material used was sterile. The prepared brains were collected in 

50ml  falcon 
tubes filled with 








4C). The supernatants were removed with the help of a 

1ml  pipette and the pellet was suspended in 

500l of complete culture medium [Dulbecco's 
modified Eagle medium (DMEM) with Glutamax I supplemented with 

10% heat-inactivated 
fetal bovine serum (FBS), 

100U ml penicillin and 

100g ml streptomycin] per brain. It will 
be referred from this point on as complete cell/culture medium. Cells were plated at a density 
of two brains per T75 culture flask and 11 ml culture medium, which was previously added.  
Cultures were maintained at 

37C in a humidified atmosphere with 

5% CO2. Culture 
medium was changed twice a week.  
2.3.2  Preparation of cell cultures for different assays 
After 10 to 14 days of culture, culture flasks were examined under the microscope to ensure 
growth and the absence of fungi. Microglial cells were isolated from the mixed glial 
(astrocytes and microglia) cultures by shaking 

200times min  for 

30min  as previously 
described by Ebert et al. (2004). Additionally, cell medium with the resuspended microglial 
was collected in 






Supernatants were removed with the exception of

5ml ; cell sediment was resuspended by 
gently mixing with a 

1ml  pipette. For quantification, 

10l of cell suspension was mixed with 
l90  tryptan blue and counted with the Neubauer Counting Chamber (twice in each harvest). 
Microglial cells were re-plated in 24-well-plates (for intracellular survival studies) and 96-
well plates (for phagocytosis and nitrite assays) at a density of approximately 

60,000cells well  and cultured in complete medium. Cells were incubated at  

37C in a 
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humidified atmosphere with 

5% CO2 for 

24h before stimulation. The harvested cell cultures 
were fed with ml10  of complete cell culture medium per flask. After 10 to 14 days the next 
harvest was done. Flasks were not harvested more than 4 times. 
2.4 Stimulation of murine microglial cells 
Microglial cell cultures were incubated for 





5% CO2. Afterwards, the supernatants were removed with the help of a 

1ml  pipette and 
discarded. Microglial cells were exposed to welll250  (in phagocytosis and nitrite assays) 
or 

500l well (in survival assays) of complete culture medium containing a TLR-agonist 
alone, MDP alone or a combination of MDP and a TLR agonist at different concentrations for 
additional 

24h. A control group with unstimulated cells, exposed to complete medium alone, 
was included in all experiments. After 

24h of stimulation, supernatants were removed using a 

1ml  pipette and collected in 96-well plates to directly perform nitrite assays or stored at 

20C until chemo-/cytokines were measured.  
2.5 Measurement of nitric oxide (NO) 
Activation of microglia can be measured by the release of nitric oxide (NO). Ebert et al. 
(2005) have previously shown that CpG and LPS stimulated microglial cells to release NO in 
a dose-dependent manner. In this work, dose response curves of NO release on microglial 
cells stimulated with MDP, poly(I:C) and Pam3CSK4 were constructed. These data were 
crucial at deciding which concentrations of ligands of the Nod2/TLR systems were used for 
later experiments. NO release was quantified in the supernatants of cells stimulated with 
different concentrations of MDP and poly(I:C) (

0.1, 0.3,1, 3,10, 30 and100g ml ) as well as 
with Pam3CSK4 (

0.000001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3,1and10g ml). 
It has been reportet that interferon gamma (IFN-γ) enhances the NO release of microglial cells 
(Häusler et al. 2002, Ebert et al. 2005). Therefore, cells which were afterwards used for 
measurement of NO release were stimulated with the TLR1/2, TLR3 or Nod2 ligand in 
complete medium supplemented with 

100U ml IFN-γ as co-stimulant. As “positive” control 
of maximal NO release (Ebert et al. 2005), microglial cells were stimulated with LPS at 

1g ml (also with 

100U ml IFN-γ as co-stimulant).  
NO release was quantified by the measurement of nitrite (NO2
-) accumulation in the 
supernatants of stimulated microglia. Nitrite, a product of living tissue, leads to a colorimetric 
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change, when adding the Griess reagent. After 24 and 

48h of stimulation, 

50l of 
supernatants were taken from each well and put into a 96-well plate. Thereafter, 

50l of 
Griess reagent was added without mixing the samples to prevent bubbles (since this would 
have affected the measurement). After short incubation time (

5 10min ), the optical density 
of each sample was measured with the Genios multiple reader at a filter of 

570nm. 
Concentrations were calculated by the comparison of absorptions with a standard curve. 
Griess reagent was prepared as follows: 
Solution A: 

1gSulfonamid  30ml100% acetic acid  70ml sterile water  
Solution B:  acid acetic%100ml60(NED)oridDihydrochlmin ethylendia-Naphthylg1.0
   watersterile ml40  




















0% depending on the amount of 
Griess reagent in the solution. In each dilution step, the same amount of sample and sterilised 
water was used. For example: 

2ml  of 

100% reagent 2ml sterilised water led to a 
concentration of 

50% of the solution. 
2.6 Measurement of microglial cell viability 
To verify microglial cell viability and exclude toxicity of the used stimuli, the water soluble 
tetrazolium salt (WST)-1 cell proliferation reagent was used. The test is based on a chemical 
reaction in the respiratory chain which only occurs in viable cells. The splitting of WST-1 by 
active mitochondria produces a soluble formazan. This reaction leads to a colorimetric change 
of the solution.  
One test for each stimulant was performed. Microglial cells were stimulated with different 
concentrations of MDP and poly(I:C) (

0.1, 0.3,1, 3,10, 30 and100g ml) as well as with 
Pam3CSK4 (

0.000001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3,1and10g ml). 
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A WST-1 solution containing one part of WST-1 reagent solved in nine parts of DMEM at 

37C was prepared (e.g. 

500l of WST-1 reagent + 

4500l of DMEM). After 

24h  of 
stimulation, cell supernatants were removed and either used for further tests or stored in 96-
well plates at 

20C until the measurement of chemo- and cytokines. Then, 

100l of WST-1 




37C in a humidified 
atmosphere with 

5% CO2. Thereafter, the optical density at 

490nm using a Genios multiplate 
reader was measured to quantify the formazan dye formed. The metabolic activity of the cells 
was directly correlated with the absorbance (Ebert et al. 2005).  
2.7 Cytokine and Chemokine release  
The levels of TNF-α, IL-6 and CXCL1 were measured by using DuoSet ELISA Development 
Kits according to manufacturer´s instructions and Regen et al. (2010). 
2.8 Bacterial strain 
For all experiments, a strain of E. coli with the antiphagocytic capsule K1, isolated from a 
child with neonatal meningitis was used (gift of Dr. G. Zysk, Institute of Medical 
Microbiology and Virology, Heinrich-Heine-University, Düsseldorf, Germany). The E. coli 
strain was suspended in a medium consisting of DMEM supplemented with 

10% FBS. For 
each assay, the concentration of the bacterial inoculum was determined by ten-fold serial 
dilutions in 

0.9% saline and quantitative plating on sheep blood agar plates. A final bacterial 
concentration of approximately 

6 106 CFU well (approximately 100 bacteria per microglial 
cell) was used for all experiments.  
2.9 Quantitative plating 
To quantify the number of bacteria in the inoculum, supernatants and lysates, 

10l of each 
sample were taken and added to 

90l sterile saline in sterile 

1ml  Eppendorf-cups. 
Additionally 

10l of this suspension were taken and plated on sheep blood agar plate with a 

1ml  pipette. For each dilution step, 

10l were taken from the new dilution and mixed with 

90l sterile saline. This was done for dilutions of 10-1, 10-2, 10-3, 10-4, 10-5 and 10-6. 
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Serial dilution: 

A  dilution of 101 : 10l sample90l saline
dilution of 102 : 10l of A90l saline
 
Once the surface on the plate was dry, the plates were incubated at 37°C for 12-24 hours 
upside down to prevent further dilution from dropping condensate. After incubation, colony-
forming units (CFUs) were counted and bacterial concentrations were expressed as

CFU ml . 
2.10 Phagocytosis assay 
After 

24h of incubation with a TLR agonist alone, MDP alone or a combination of both, 
supernatants were removed and stored at 

20C until measurement of chemo- and cytokines. 
Thereafter, cells were washed with warm PBS by using a 

1ml  pipette. PBS was added and 
removed carefully without touching the ground of the well plate to prevent destruction of the 
cell cultures. The pipette was changed after each well. Ribes et al. (2009) have shown that a 
multiplicity of infection of about 100 bacteria per microglial cell was optimal for phagocytosis 
assays involving E. coli strains. On the basis of these results, this concentration was used for 
all following experiments. Therefore a bacterial suspension with E. coli K1 at a concentration 
of about 

2.5 107 CFU ml was prepared and 

0.25ml  of the solution was added to each well 
of the 96-well plate. Bacteria were co-incubated for 30 and 






5%  CO2). Afterwards, the supernatants were removed, serially 
diluted in 

0.9% saline and plated on sheep blood agar plates to determine the number of 
extracellular bacteria in the supernatants. Microglial cells were washed twice with warm PBS 
and incubated for 

1h in a solution of DMEM containing 

200g ml gentamicin (Sigma-
Aldrich, St. Louis) to kill all extracellular nonphagocytosed bacteria (Nazareth et al. 2007). 
Supernatants were removed and the cell monolayers were washed twice with warm PBS 
before lysing them with 

100l of distilled water. Quantitative plating of the lysates on sheep 
blood agar was performed to enumerate the intracellular surviving E. coli K1. To confirm the 
bactericidal effect of gentamicin, supernatants were plated after 

1h of antibiotic incubation. 
The extracellular amount of bacteria was found to be below 

10 CFU well  in each experiment.  
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2.11 Cytochalosin D inhibition assay 
The re-organization of the actin cytoskeleton is essential for the process of phagocytosis (May 
and Machesky 2001). Cytochalasins are fungal metabolites inhibiting actin polymerization 
(Cooper 1987) and therefore inhibit the process of phagocytosis. To verify whether bacteria 
found on microglia are phagocytosed or invaded the cells, cytochalasin D (CD) was used. 
Nazareth et al. (2007) showed that CD inhibits phagocytosis of E. coli for up to 

99%. In the 
current work, CD was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 

4nM 
and stored at 

20C until use. Microglial cells cultures were prepared and stimulated with the 
Nod2 and TLR agonists for 

24h as previously described. Afterwards, a final concentration of 

10M CD well was added to the cell monolayers for 

30min  prior to the addition of bacteria 
and was present until the end of the experiment (Ribes et al. 2009). The number of bacteria in 
the supernatants from microglia treated with and without CD was quantified after 

90min  of 
bacterial incubation to assure that CD did not influence bacterial replication.  
2.12 Intracellular survival assay 
Cells were harvested, plated into 24-well-plates and stimulated as previously described. To 
control whether phagocytosed E. coli K1 were able to survive or even replicate inside 
microglial cells, microglia were given 






5%  CO2). Thereafter, 

500l of DMEM containing 

200g ml of gentamicin were added, 
and cells were incubated for up to

6h. After 60, 150, 240, 

330min  of incubation, supernatants 
were removed with a 

1ml  pipette and stored at

20C. Thereafter, cells were washed twice 
with warm PBS. Finally, PBS was removed and cells were lysed with 

300l of distilled 
water by mixing with a 

1ml  pipette. The lysates were quantitatively plated on sheep blood 
agar plates to determine the number of intracellular surviving E. coli K1.  
2.13 Statistical analysis 
GraphPad Prism software was used to perform statistical analysis and graphical presentation. 
Kolmogorov-Smirnov statistical test showed that some data were not normally distributed. 
Therefore, all data were analysed by two-tailed Kruskal-Wallis test. When Kruskal-Wallis 
showed a

p value of  0.05, selected comparisons between two groups were performed by 
using two-tailed Mann-Whitney U-test. To correct for repeated testing we used the 
Bonferroni-Holm method (Holm 1979).
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3 Results 
3.1 NO release assays 
As previously described, NO was used as a parameter to measure and correlate microglial 
activation of the different agonists used in this study. A stimulation time of at least 24 h was 
chosen as previous experiments had shown that measurements after shorter incubation times 
with TLR ligands caused milder NO release (Ebert et al. 2005). Since previous experiments 
had shown the NO dose response curves for TLR4 and TLR9 agonists (Ebert et al. 2005) this 
work focused on studying the NO release upon stimulation of microglial cells with MDP, 
Pam3CSK4 and poly(I:C) (agonists of Nod2, TLR 1/2 and TLR3, respectively).  
The WST-1 test showed no cytotoxic effect of MDP, Pam3CSK4 or poly(I:C) at any 
concentration studied in microglial cells. 
Ebert et al. (2005) described LPS as the strongest stimulants of NO release. To compare the 
potency in terms of NO release of the tested stimuli [MDP, Pam3CSK4 and poly(I:C)] I 
compared my results with the magnitude of NO release by LPS described by Ebert et al. 
(2005). For an optimised comparison, I chose the results found after stimulation with 

0.1g ml of each agonist [MDP, Pam3CSK4, poly(I:C), LPS and CpG] as this concentration 
was tested in all groups. 
3.1.1 NO release after stimulation with MDP  
Stimulation of microglial cells with MDP induced the production of low amounts of NO. The 
release of NO after 24 h of stimulation were not potent enough to determine the half-
maximum stimulating effect on microglial cells (EC50) assessed from the dose-response curve 
at chosen concentration (Figure 3.1). I did not test higher concentrations as those would be 
unphysiologically high.  MDP at 

0.1g ml and 






9.2% of the NO released after stimulation with 

0.1g ml LPS. 
Additionally I measured NO release after 48 h of stimulation with MDP at same 
concentrations. Here, marginal higher amounts of NO release were measured (Figure 3.2). 
For further experiments, I decided to use a concentration of 

10g ml MDP as the lowest 
concentration inducing the maximum NO release attainable with MDP as well as a 
submaximum concentration of 

0.1g ml MDP to demonstrate the synergistic effect of MDP 
in combination with TLR agonists.  
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100g ml. Data are shown as mean ± SD. 
 
 

















Figure 3.2 NO concentrations after 
















100g ml. Data are shown as mean ± SD. 
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3.1.2 NO release after stimulation with poly(I:C) 
To determine the appropriate concentration of the TLR3 agonist poly(I:C) to stimulate 
microglial cells, NO assays were performed as previously described. The EC50 assessed from 
the sigmoidal dose response curve of NO release after 

24h of stimulation was 

4.3g ml 
(Figure 3.3). Poly(I:C) at 

0.1g ml and 






the NO release measured in cells stimulated with 

0.1g ml LPS. These results are 
comparable to the levels of NO measured after stimulation with MDP at the same 
concentrations. 
 
3.1.3 NO release after stimulation with Pam3CSK4 
The EC50 assessed from the sigmoidal dose response curve of NO release after 

24h  
stimulation with different concentrations of Pam3CSK4 was 

0.002g ml as demonstrated in 
Figure 3.4. Pam3CSK4 at 

0.001g ml and 






of the NO release reached after stimulation with 

0.1g ml LPS. Compared to cells stimulated 
with MPD or poly(I:C), microglia stimulated with Pam3CSK4 released about five times more 
NO at a concentration of 

0.1g ml. 



















 Figure 3.3 NO release after 















100g ml. Data are shown as mean ± SD. 
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The lowest concentration inducing maximum NO release (from now on referred as the 
maximum concentration of the agonist) was chosen according to published data in case of 
agonists of TLR4 (LPS) and TLR9 (CpG) (Ebert et al. 2005, Ribes et al. 2009) and NO assays 
described in the current work in case of ligands of Nod2 (MDP), TLR1/2 (Pam3CSK4) and 
TLR3 [poly(I:C)]. To investigate further studies on synergism of the combination of MDP 
and a TLR ligand, for each stimulant a concentration inducing a factor of 

102 NO release 
compared to each maximum concentration was chosen. From now on I will refer to that as the 
submaximum concentration of the agonist. 
3.2 Release of chemo- & cytokines  
Ribes et al. (2009) showed that murine TLR-stimulated microglial cells (TLR agonists used as 
the maximum concentration in terms of NO release) released significantly higher levels of 
chemo- and cytokines compared to unstimulated cells. Stimulation with TLR1/2 (Pam3CSK4), 
TLR4 (LPS), TLR9 (CpG) agonists led to comparable amounts of TNF-α release, whereas the 
























Figure 3.4 NO release after h24  of microglial stimulation with Pam3CSK4 at 
0.000001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 

10g ml. Data are 
shown as mean ± SD. 
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levels of CXCL1 differed significantly among the stimulated groups. The maximum amounts 
of CXCL1 release were measured after stimulation with 

0.1g ml Pam3CSK4, followed by 

0.1g ml CpG. The lowest amounts of CXCL1 were measured in cells previously stimulated 
with 

0.01g ml LPS (Ribes et al. 2009). 
In the current work, concentrations of TNF-α, CXCL1 and IL-6 were measured in the 
supernatants of microglial cells (

n 6wells group ) after 

24h of incubation with either the 
different TLR agonists at submaximum concentration or MDP at sub/maximum 
concentrations alone (Figure 3.5) as well as with MDP at 

0.1g ml and 

10g ml in 
combination with the submaximum concentrations of TLR agonists [

0.001g ml Pam3CSK4, 

0.1g ml poly(I:C), 

0.0001g ml LPS, 

0.01g ml CpG] (data shown in Figure 3.6, Figure 
3.7, Figure 3.8).  
3.2.1 Release of chemo- and cytokines after stimulation with a single agonist 
Unstimulated cells and cells stimulated with 

0.1g ml MDP or 

0.01g ml CpG did not 
release measurable amounts of TNF-α, CXCL1 and IL-6 (Figure 3.5). Compared to 
measurements with higher concentrations of CpG (Ribes et al. 2009), these results led to the 
conclusion that the concentration of CpG used in this work was too low to evoke chemo- and 
cytokine release by microglial cells. 
Stimulation with maximum MDP concentration as well as stimulation with submaximum 
concentrations of Pam3CSK4, poly(I:C) and LPS alone induced significantly higher release of 
TNF-α compared to the unstimulated control group [

p  0.001 for MDP, 

p  0.001 for 
Pam3CSK4, poly(I:C) and 

p  0.01 for LPS] (Figure 3.5). Significantly higher CXCL1 levels 
were detected after incubation with Pam3CSK4 (

p  0.001) or LPS (

p  0.01) alone compared 
to unstimulated cells, whereas all other tested groups were devoid of release. The only single 
stimulant causing significantly higher concentration of IL-6 compared to the control group of 
cells was LPS (

p  0.0001). 
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3.2.2 Release of chemo-/cytokines upon co-stimulation with MDP and TLR agonists 
The next step was to find out whether microglial chemo-/cytokine release increased if cells 
were co-stimulated with MDP and one TLR agonist at the same time. Therefore, cells were 
incubated in medium containing MDP at 

0.1g ml or 

10g ml in combination with 
submaximum concentrations of TLR ligands for 

24h and then measurement of TNF-α, 
CXCL1 and IL-6 levels was performed in the supernatants (Figure 3.6, Figure 3.7, Figure 3.8 
respectively). 
Microglia co-stimulated with CpG at submaximum concentration and MDP did not release 
measurable amounts of chemo- and cytokine release. Significantly increased concentrations 
of TNF-α were observed after co-incubation of poly (I:C) with 

0.1g ml MDP (

p  0.01) as 
well as for Pam3CSK4 or poly(I:C) with 

10g ml MDP (




























































































































Figure 3.5  Chemo- and cytokine release after stimulation with one compound [MDP, 
TLR1/2 (Pam3CSK4), TLR3 [poly(I:C)], TLR4 (LPS) and TLR9 (CpG)] 
agonists.  
Data are shown as medians (

25% 75% interquartile ranges). 

n  6 17wells group . Data were analysed by Mann–Whitney U-test and 




 p  0.01, 

p  0.001 compared to the unstimulated group. 
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TNF-α release was seen when cells were stimulated with LPS in combination with 
sub/maximum doses of MDP (

p  0.001) (Figure 3.6). 
 
Similarly, CXCL1 levels (Figure 3.7) increased significantly after co-stimulation of 
Pam3CSK4 or LPS with 

0.1g ml MDP (

p  0.05 and






p  0.01 and 

p  0.001, respectively) compared to stimulation with each agonist alone. 
The combination of MDP with either TLR3 [poly(I:C)] or TLR9 (CpG) agonists failed to 















































































































































Figure 3.6 TNF-α release after stimulation with mlg0.1  and mlg10 MDP and 
submaximum concentrations of TLR1/2 (Pam3CSK4), TLR3 [poly(I:C)], 
TLR4 (LPS), TLR9 (CpG) agonists.  
Data are shown as medians (

25% 75% interquartile ranges); 

n  6 18wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method. 

p  0.05 
compared to unstimulated control, 

 p  0.01, 

p  0.001 compared to 
TLR agonists alone. 
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As mentioned in Figure 3.8, the release of IL-6 was increased when LPS was combined with 
either low (

p  0.01) or high concentrations of MDP (

p  0.001). Whereas single stimulation 
with Pam3CSK4 and poly(I:C) failed to cause significant release of IL-6, significantly higher 
levels were found in the supernatans of microglia stimulated with poly(I:C) combined with 
submaximum MDP concentration (






p  0.01) or 

0.1g ml MDP (
















































































































































Figure 3.7 CXCL1 release after stimulation with mlg0.1  and mlg10 MDP and 
submaximum concentrations of TLR1/2 (Pam3CSK4), TLR3 [poly(I:C)], 
TLR4 (LPS), TLR9 (CpG) agonists.  
 
 
Data are shown as medians (

25% 75% interquartile ranges); 

n  6 18wells group . Data were by Mann–Whitney U-test and corrected 
for repeated testing with the Bonferroni–Holm method. 

p  0.05, 

 p  0.01, 

p  0.001 compared to TLR agonist alone. 
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3.3 Phagocytosis assays 
After microglial stimulation, a bacterial suspension with E. coli K1 at a concentration of 

2.5 107 CFU ml was added for 

30min  or 

90min  to allow phagocytosis. Quantitative 
plating of the lysates on sheep blood agar was performed to enumerate E. coli K1 surviving 
intracellularly. For each independent experiment, the phagocytic rate of E. coli K1 quantified 
in unstimulated cells was considered to be 

100%. Thereafter, the number of bacteria ingested 
by the stimulated groups was calculated as the percentage of the amount of E. coli K1 
ingested by the unstimulated group. The n-values in every experiment differ because control 
groups and MDP stimulated groups were included in every experiment and therefore have 
higher n-values. 
3.3.1 Phagocytosis after stimulation with MDP  
Microglial cells were incubated with sub/maximum concentrations of MDP. Thereafter, cells 
were co-incubated for 

30min  and 

90min  to phagocytose bacteria as shown in Figure 3.9. 












































































































































Figure 3.8 IL-6 release after stimulation with mlg0.1  and mlg10 MDP and  
  submaximum concentrations of TLR1/2 (Pam3CSK4), TLR3 [poly(I:C)], 
  TLR4 (LPS), TLR9 (CpG) agonists. 
 Data are shown as medians (

25% 75% interquartile ranges); 

n  6 18wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method. 

p  0.05, 

 p  0.01, 

p  0.001 compared to TLR agonist alone. 
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concentration of MDP, phagocytosed more bacteria than cells stimulated with submaximum 
concentration of MDP after 

30min of co-incubation with E. coli K1 (

p  0.001; 

p  0.05, 

n  69  77 wells group ).  





p  0.001 for MDP at 

0.1g ml and 

10g ml with respect to the unstimulated 
group), with the highest rate of phagocytosis calculated in cells previously stimulated with 

10g ml MDP (

n  89 93 wells group ).  
At both tested time points, maximum concentrations of MDP caused significantly higher 
phagocytosis rates compared to submaximum concentration (





p  0.0001 
at 

90min ).  
 
3.3.2 Phagocytosis after stimulation with poly(I:C)  
To determine whether microglia ingest more bacteria after co-incubation with the viral TLR3 
agonist poly(I:C), cells were stimulated for 





























































































Figure 3.9 MDP stimulation enhanced phagocytosis of E. coli K1 after 

30min (A) and 
90min  (B) of incubation. 
A) B) 
Data are shown as medians (

25% 75% interquartile ranges); A) 

n 6977 and B) 

n  8393wells group . Data were analysed by Mann–
Whitney U-test and corrected for repeated testing with the Bonferroni–
Holm method. 

p  0.05, 

p  0.001 compared to unstimulated 
microglial cells.  
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and maximum (

10g ml) concentrations. Thereafter, cells were challenged for 

30min  
(Figure 3.10 A) and 

90min  (Figure 3.10 B) with E. coli K1.  
After 

30min  of exposure, cells stimulated with poly(I:C) at 

0.1g ml and 

10g ml ingested 
more bacteria than unstimulated cells (

p  0.05, 

p  0.01, respectively). An increase in the 
time of co-incubation of poly(I:C)-stimulated cells and bacteria up to 

90min  led to higher  
phagocytic rates compared to the unstimulated group (

p  0.001).  
 
 
3.3.3 Phagocytosis inhibition studies with CD 
The ingestion of E. coli K1 was reduced by 

> 90% after 

90min  of phagocytosis in cells 
treated with CD compared to the group without CD as presented in Figure 3.11. This indicates 











































































































Figure 3.10 Phagocytic rates in poly(I:C)-stimulated microglia in (A) 







Data are shown as medians (

25% 75% interquartile ranges); A) 

n 14 20wells group  and B) 

n 19 20wells group . Data were 
analysed by Mann–Whitney U-test and corrected for repeated testing with 
the Bonferroni–Holm method. 

p  0.05, 

p  0.001 compared to 
unstimulated microglial cells. 
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rearrangement of the actin cytoskeleton. The inhibitory effect of CD on the action of TLR1/2 
(Pam3CSK4), TLR4 (LPS), TLR9 (CpG) agonists were already shown by Ribes et al. (2009). 
 
 
3.3.4 Comparison of the phagocytic rates after stimulation of the Nod2 and TLR 
systems 
Prior experiments had shown that MDP and poly(I:C) enhanced phagocytosis of E. coli K1. It 
is known that Pam3CSK4, LPS and CpG activate murine microglial cells to ingest more 
bacteria (Ribes et al. 2009). Therefore, the next question addressed was to compare the 
magnitude of the responses achieved with poly(I:C)- and MDP-stimulated cells compared to 
cells activated with the other TLR agonists. Therefore I compared the phagocytic rate of 
microglial cells previously exposed to each agonist (MDP, Pam3CSK4, poly(I:C), LPS or 
CpG) at submaximum and maximum concentrations. Microglial cells were stimulated for 

































































Figure 3.11 Inhibitory effect of cytochalasin D (CD) on phagocytosis of E. coli K1.  
 Data are shown as medians (

25% 75% interquartile ranges). 

n  5 16wells group . Phagocytosis of unstimulated cells that were not 
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In all groups and time points, cells stimulated with either Nod2 or TLR ligands had a higher 
phagocytic rate than unstimulated microglia. Stimulation with most of the tested TLR 
agonists alone induced stronger microglial phagocytosis than the Nod2 system alone after 

30min  (Figure 3.12) and 

90min  (Figure 3.13) of challenge with E. coli K1. Except for 
poly(I:C)-stimulated cells, microglia stimulated with agonists at maximum concentration 
ingested more bacteria than cells stimulated with agonists at submaximum concentration 
(Figure 3.13).  
In the 

30min  phagocytosis assays (Figure 3.12), higher numbers of ingested bacteria were 
counted in cells stimulated with submaximum concentrations of CpG (

p  0.001) and 
Pam3CSK4 (

p  0.01) than in groups incubated with submaximum concentrations of 
poly(I:C), MDP or LPS. The highest numbers of ingested bacteria were quantified in cells 
stimulated with maximum concentrations of CpG, LPS and followed by Pam3CSK4 and MDP 
(all

p  0.001) and poly(I:C) (





























































































Figure 3.12 Stimulatory effect of agonists of the MDP and TLR systems on phagocytosis 
after 30min  of co-incubation of microglia and bacteria.  
 Data are shown as medians (

25% 75% interquartile ranges). 

n 10  78wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method. 

 p  0.01, 

p  0.001 compared to unstimulated control. 
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When bacteria were incubated for 

90min  with cells stimulated with submaximum 
concentrations, phagocytic rates were higher in the Pam3CSK4, poly(I:C) and LPS groups 
(

p  0.001) than in the MDP or CpG groups (

p  0.01) (Figure 3.13). For groups of cells 
stimulated with maximum concentrations, the highest phagocytic rates were achieved in the 
CpG, LPS groups followed by the Pam3CSK4, MDP or poly(I:C) groups (all 

p  0.001). In 
contrast to the co-incubation for 

30min , stimulation with LPS at submaximum concentration 
led to a higher phagocytic rate than the rate observed in unstimulated cultures (

p  0.001) 
(Figure 3.13). 
 
3.3.5 Phagocytosis after co-stimulation of MDP and TLR agonists  
In all experiments, unstimulated microglia cells ingested the lowest number of bacteria. After 
having shown that MDP had a stimulatory effect on microglial cells, I chose MDP as the 
reference control group instead of unstimulated cells for all graphs showing co-stimulation of 
































































































Figure 3.13 Stimulatory effect of MDP and TLR after 
















Data are shown as medians (

25% 75% interquartile ranges). 

n 1160wells group . Data were analysed by Mann–Whitney U-test 
and corrected for repeated testing with the Bonferroni–Holm method. 

 p  0.01, 

p  0.001 compared to unstimulated control. 
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effect between these two pathways. A synergistic effect of a combination on E. coli 
phagocytosis was assumed when the phagocytic rate by the combination was significantly 
higher ( 05.0p ) than the phagocytic rate by each agonist alone. 
3.3.5.1 Phagocytosis after 30 min of incubation with E. coli K1 
The addition of MDP enhanced the phagocytic rates of cells treated with submaximum 
concentrations of TLR ligands [poly(I:C), LPS, CpG] as shown in Figure 3.14 for mlg1.0   
MDP and Figure 3.15 for 

10g ml MDP. A synergistic bacterial uptake was observed when 
sub/maximum concentrations of MDP were tested with submaximum and maximum 




p  0.0001 respectively). Also, the addition of 

10g ml 
MDP to submaximum concentration of poly(I:C) or CpG had a synergistic effect on the 
phagocytic rate (

p  0.05) (Figure 3.15). The addition of MDP at mlg1.0   or 

10g ml to 
Pam3CSK4 at submaximum concentration did not increase phagocytosis. 
    3 Results 













































































































Figure 3.14 Synergistic effect on 

30min phagocytosis after stimulation with 




Data are shown as medians (

25% 75% interquartile ranges); 

n 12  79wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method.  

 p  0.01 compared to TLR agonist alone. 
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Figure 3.15 Synergistic effect on 

30min phagocytosis after stimulation with mlg10  
MDP and submaximum concentrations of TLR agonists.  
 Data are shown as medians (

25% 75% interquartile ranges); 

n 12  78wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method. 

p  0.05, 

p  0.0001 compared to TLR agonist alone. 
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Co-stimulation with TLR agonists at maximum concentration and mlg10  MDP (Figure 
3.16) resulted in nearly same amounts of phagocytosed bacteria compared to combinations 





























































































Figure 3.16 Synergistic effect on 

30min phagocytosis after stimulation with maximum 
concentrations of MDP and TLR agonists. 
 There was no increasing effect on phagocytosis after co-stimulation of 
TLR1/2, 3, 4 and 9 agonists and MPD at maximal concentration. Data are 
shown as medians (

25% 75% interquartile ranges),

n 10 82wells group . 
Data were analysed by Mann–Whitney U-test and corrected for repeated 
testing with the Bonferroni–Holm method.  Although data show high ranges 
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3.3.5.2 Phagocytosis after 90 min of incubation with E. coli K1 
Similar to the results in the 

30min  phagocytosis assays, the addition of MDP enhanced the 
phagocytic rates of cells treated with submaximum concentrations of TLR ligands after 

90min  of E. coli K1 challenge. Synergism was observed when sub/maximum concentrations 
of MDP were co-incubated with submaximum concentrations of Pam3CSK4 (

p < 0.05) and 
CpG (

p < 0.01) (Figure 3.18 and Figure 3.19). In contrast to the observations in 

30min  
phagocytosis assays, the combination of MDP and submaximum doses of LPS did not show a 
synergistic effect on phagocytosis (Figure 3.20 and Figure 3.21) whereas those combinations 
let to a significant rise of the release of tested chemo- and cytokines in the cultures 


























































































Figure 3.17 Synergistic effect on 

30min phagocytosis of E. coli K1 after stimulation 
with mlg0.1  MDP and maximum concentrations of TLR agonists. 
 Data are shown as medians (

25% 75% interquartile ranges). 

n 10  72wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method. Although 
data show high ranges of differences it was not statistically different 
because of the statistical spread.  
 
.  
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Figure 3.18 Co-stimulation of Nod2 and TLR agonists at submaximum concentration 
after 

90min of exposure to E. coli K1. 
 
 
Data are shown as medians (

25% 75% interquartile ranges). 

n 1153wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method. 

p  0.05, 

 p  0.01 compared to TLR agonist alone. 
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Figure 3.19 Stimulatory effect of 

10g ml MDP and TLR agonists at submaximum 
concentration after 

90min of exposure to E. coli K1. 
Synergistic effect could be seen after adding MDP to TLR1/2, TLR3 and 
TLR9 agonists [Pam3CSK4, poly(I:C) and CpG]. Data are shown as 
medians (

25% 75% interquartile ranges); 

n 15 62wells group . Data 
were analysed by Mann–Whitney U-test and corrected for repeated testing 
with the Bonferroni–Holm method. 

p  0.05, 

 p  0.01 compared to 
TLR agonist alone. 
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Figure 3.20 Co-stimulation of MDP and TLR agonists at submaximum concentration 
after 

90min of exposure to E. coli K1. 
Data are shown as medians (

25% 75% interquartile ranges). 

n 1155wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method. 

p  0.05, 

 p  0.01 compared to TLR agonist alone. 
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A synergistic effect of the phagocytic rate was found when cells were co-stimulated with 
MDP in combination with maximum concentrations of Pam3CSK4 (p < 0.05) (Figure 3.21) 
and poly(I:C) (

p < 0.05) (Figure 3.21 and Figure 3.22). Addition of MDP to LPS and CpG 
failed to reach any statistical significance.  
 
Co-stimulation of MDP and TLR agonists both at maximum concentrations led to a 
significant increase of bacterial uptake only in case of poly(I:C) (Figure 3.22) whereas the 
combinations with Pam3CSK4 and LPS failed to stimulate phagocytosis significantly 
compared to the phagocytic rates achieved by the TLR agonist at maximum concentration. In 
case of a co-stimulation with MDP and maximum concentrations of CpG, the phagocytic rate 





































































































Figure 3.21 Phagocytosis after co-stimulation with 

0.1g ml  MDP and TLR agonists 
at maximum concentration after 

90min of exposure to E. coli K1. 
Data are shown as medians (

25% 75% interquartile ranges); 

n 1155wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method; 

p  0.05 
compared to the TLR agonist alone.   
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3.4 Intracellular survival assay 
After demonstrating the enhanced ability of microglial cells to phagocytose bacteria upon 
stimulation with MDP or poly(I:C) alone, as well as with the combination of MDP and certain 
TLR agonists, I studied whether stimulated microglia could eliminate ingested bacteria at 
higher rates than unstimulated cells. The intracellular survival assays were performed with 

10g ml MDP and submaximum concentrations of TLR agonists alone (Figure 3.23) and 
with 

10g ml MDP in combination with submaximum concentrations of TLR agonists 
(Figure 3.24). A control group with unstimulated cells was included in all experiments. The 

































































































Figure 3.22 Stimulation with Nod2 and TLR agonists at maximum concentration after 

90min of exposure to E. coli K1.  
Data are shown as medians (

25% 75% interquartile ranges); 

n 12 50wells group . Data were analysed by Mann–Whitney U-test and 
corrected for repeated testing with the Bonferroni–Holm method; 

p  0.05 
compared to TLR agonist alone.  
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different time points (

60,150, 240, 330min ). In all groups, the amount of intracellular 
surviving bacteria decreased throughout the experiment (Figure 3.23 and Figure 3.24). To 
determine whether there is a synergistic effect on intracellular killing, statistical analyses were 
shown in Table 3.1. The n-values in every experiment differ because control groups and MDP 




































































Figure 3.23 Time course of bacterial killing of E. coli K1 after single stimulation with 










For each group, intracellular survival is expressed as the number of 
recovered bacteria expressed in logarithmic scale at the different time 
points. Data at different time points is shown as median; 

n  6  30wells group . 
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Figure 3.24 Time course of bacterial killing after combined stimulation with 

10g ml 







For each group intracellular survival is expressed as the number of 
recovered bacteria expressed in logarithmic scale at the different time 
points. Data at different time points are shown as median; 

n  6  30wells group . 
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For each group, the absolute amount of killed bacteria was calculated as the difference 
between each individual value at 

330min  and the median of ingested bacteria of the 
respective group after 

60min  of gentamicin exposure, which I defined as initial point in Table 
3.1. Stimulation of microglia with either MDP or one TLR agonist alone increased the 
number of phagocytosed bacteria (initial point) and killed bacteria in comparison to 




p  0.001) (Table 3.1). The combined stimulation of 
microglial cells with MDP and Pam3CSK4 or LPS resulted in significantly higher intracellular 
killing of E. coli K1, compared to cells stimulated with each agonist alone (

p  0.001). In 
contrast, the combinations of CpG with MDP and MDP with poly(I:C) slightly reduced the 
number of intracellular killed bacteria (

p  0.05) (Table 3.1).  
 
Table 3.1 Intracellular survival 
 
 
Phagocytosed E. coli 
K1 at initial point 
 Intracellularly killed E. coli K1  
 after 330 min 
    
medium 835 (612 / 1218) †† 743 (687 / 784) ††  
    
MDP 10 1350 (1000 / 1830) 1195 (1045 / 1260)  
 
P3C 0.001 16000 (12200 / 18500) 14957 (14330 / 15411)  
P3C0.001+MDP10 20000 (16500 / 27500) 18873 (18629 / 19020)***  
    
Poly(I:C)0.1 11834 (9017 / 13062) 9883 (9184 / 10044)  
Poly (I:C)0.1+MDP10 12359 (10113 / 13967) 9849 (8896 / 10121)  
    
CPG 0.01  2200 (1288 / 6375) 2100 (1733/2148)  
CPG 0.01 + MDP10 1610 (1325 / 14275) 1440 (1064 / 1478)  
 
LPS 0.0001 5650 (4738 / 8708) 4390 (3800 / 4830)  
LPS 0.0001+MDP10 7900 (6450 / 9167) 6920 (5825 / 7027)***  
    
    
   
   
 
Data are shown as medians (25 % / 75 % interquartile ranges). Data were analysed 
by Mann–Whitney U-test and corrected for repeated testing with the Bonferroni–
Holm method; n=6–30 wells/group. Data were from at least three independent 
experiments.  Difference between unstimulated and every stimulated group were 
statistical significant. ††p < 0.0001 compared to stimulation with all agonists, ***p 
< 0.001 compared to TLR agonists alone. Difference between unstimulated and 
every stimulated group alone was statistical significant. 
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4 Discussion 
TLRs and Nod-like are examples of germline-encoded PRRs, which enable innate immunity 
to detect PAMPs (Medzhitov and Janeway 2000, Akira et al. 2006). Microglial cells are the 
local macrophages of the CNS (Hanisch and Kettenmann 2007) and express different 
members of the TLR family (TLR1-9), which sense diverse PAMPs such as lipopeptides, 
virus-derived double-stranded DNA and LPS (Olson and Miller 2004). Furthermore, they 
express Nod2 and low levels of Nod1 (Sterka and Marriott 2006). NOD2 functions as an 
intracellular receptor of the minimal PGN motif common to all bacterial PGN: MDP 
(Girardin et al. 2003). After the recognition of pathogens, microglias have various functions 
and abilities such as the release of NO, chemo- and cytokines or the transformation into a 
phagocytic phenotype (Hanisch and Kettenmann 2007, Ribes et al. 2009).  
Measurements of NO release were performed to assess microglial activation. In case 
of LPS and CpG, the minimal concentration inducing maximum NO release were chosen 
according to previously published data (Ebert et al. 2005), where LPS at a concentration of 
1µg/ml was defined as the strongest stimulant inducing maximum NO release (

100%). In the 
present work, NO assays were performed to detect the lowest concentration of Pam3CSK4, 
poly(I:C) and MDP inducing maximum NO release. As submaximum concentration inducing 
NO release, a concentration 100 times lower was chosen. The results showed that the viral 
TLR3 agonist poly(I:C) and the Nod2 ligand MDP elicited nearly the same amounts of NO 
when microglia were stimulated with the same concentrations of each stimulant. MDP and 
poly(I:C) achieved only about 

7% of the maximum NO release whereas a stimulation with 
Pam3CSK4 elicited about 

36% compared to cells stimulated with  mll1.0  LPS.  
In a previous report microglia stimulated with 

0.01l ml  LPS and 

1l ml  CpG, the 
lowest concentrations inducing maximum NO release, (Ebert et al. 2005) ingested comparable 
numbers of E. coli K1 in 

30min  and 

90min  phagocytosis assays (Ribes et al. 2009). These 
findings indicated that the ability of stimulated microglia to ingest bacteria might correlate 
with NO release. However, in the present study this correlation was not seen with all tested 
stimuli. Whereas cells previously stimulated with e.g. the viral TLR3 agonist poly(I:C) and 
the Nod2 ligand MDP released the same amount of NO when tested at same concentration, 
the number of ingested bacteria after 

90min  of exposure to E. coli K1 was about three times 
higher in poly(I:C)-stimulated cells (Figure 3.9 and Figure 3.10). These findings were 
observed for other stimuli and concentrations as well. Therefore, I assume that NO can be 
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considered as one indicator of the magnitude of cell activation promoted by each single 
stimulant but does not allow comparisons among different stimuli. Possibly an experimental 
setting for phagocytosis and intracellular killing with concentrations of stimuli that elicit the 
same amount of NO would have allowed a more accurate conclusion concerning the potency 
of low concentrations. The same observation can be made in terms of release of pro-
inflammatory molecules such as TNF-α, CXCL1 and IL-6. These are known indicators of cell 
activation that support the immune system in pathogen clearance (Sterka et al. 2006, Ribes et 
al. 2009) but in case of overstimulation of the immune system could lead to fatal 
consequences (Aloisi 2001). Figure 3.5 shows that Pam3CSK4-stimulated cells released the 
highest amount of TNF-α and CXCL1, whereas cells stimulated with MDP and CpG at 
submaximum concentrations were nearly devoid of chemo- and cytokine release. Concerning 
MDP, similar results were found in further investigations on the release of chemo- and 
cytokines (Ribes et al. 2012). Whereupon a stimulation with the viral TLR3 agonist poly(I:C) 
elicited only significant levels of TNF-α. Chemo- and cytokine release showed that, in case of 
stimulation with submaximum concentrations, the TLR system elicits stronger activation of 
microglial cells than the Nod2 system. The low chemo-/cytokine release observed after 
stimulation with submaximum concentrations of MDP ( mll1.0  ) and CpG (

0.01l ml) 
could be interpreted as these tested concentrations failed to cause a significant level of 
stimulation necessary for the elimination of invading pathogens. However, further 
experiments studying in more detail pathogen phagocytosis and survival assays revealed that 
this was not true. Therefore the question is whether measurement of NO release is the only 
way to determine cell activity. 
The next question addressed was to find out whether stimulated microglia were able to kill 
more ingested bacteria than unstimulated cells. Stimulation with TLR1/2, TLR4 and TLR9 
agonists enhanced phagocytose and intracellular killing of E. coli (Ribes et al. 2009).  
Phagocytosis and intracellular survival assays showed that microglia exposed to MDP or 
poly(I:C) ingested and killed higher numbers of a pathogenic E. coli K1 strain compared to 
unstimulated cells although cells stimulated with MDP “did not significantly augment the 
basal expression of cell surface molecules for antigen presentation and T cell stimulation” 
(Ribes et al. 2012, p 21). Microglial stimulation with submaximun and maximum 
concentrations of MDP and poly(I:C) increased phagocytosis as well as intracellular killing of 
E. coli K1 despite the low release of tested chemo- and cytokines. However, the percentages 
of bacterial uptake in MDP and poly(I:C)-treated cells were lower than in cells stimulated 
with maximum concentrations of Pam3CSK4, LPS or CpG similarly to the previously 
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described release of chemo- and cytokines. The number of surviving intracellular E. coli K1 
decreased after stimulating murine microglia with agonists of TLR1/2 (Pam3CSK4), TLR4 
(LPS) and TLR9 (CpG) at maximum concentration in terms of NO release (Ebert et al. 2005, 
Ribes et al. 2009). Here, I was able to show that this is not only true for cells stimulated with 
submaximum concentrations of the above mentioned agonists but also for poly(I:C) and 
MPD. Furthermore, the addition of maximum concentrations of MDP to cells stimulated with 
TLR agonists led to higher numbers of intracellular killed bacteria in case of LPS-MDP and 
Pam3CSK4-MDP combinations. This suggests a possible augmentation of selected microglial 
functions upon stimulation with these particular combinations. In contrast, the absolute 
number of intracellular killed bacteria was lower when maximum concentrations of MDP 
were added to submaximum concentrations of poly(I:C) and CpG compared to those found 
after stimulation with the agonists alone.  
In case of infection, different PRRs located either on the cell surface or in intracellular 
compartments might recognize the invading pathogen at the same time. Sterka and Marriott 
(2006) showed an upregulation of Nod2 expression after exposure to Gram-negative bacteria, 
MDP and TLR4 and TLR5 ligands. The next aim was to find out whether a potential 
collaboration of the NOD and TLR system enhanced microglial responses. Guo et al. (2006) 
showed an increased expression of P2X4R, a purinergic ion channel receptor having a central 
role in CNS inflammation in rat microglia (Guo and Schluesener 2005) after stimulation with 
MDP plus TLR agonists. Experiments with murine peritoneal macrophages, human 
mononuclear (Netea et al. 2005) and dendritic cells (Kramer et al. 2006) showed an increase 
of TLR2 mediated pro- and anti-inflammatory molecules through co-stimulation with MDP as 
well as modulator effects of NOD2 on TLR3 and TLR4 signalling, whereas no effect could be 
found for TLR9. The same could be found with respect to the release of chemo- and cytokines 
in the present work. Watanabe et al. (2004) described an inhibitory effect on the release of IL-
12 and IFN-γ when dendritic cells were stimulated with Pam3CSK4 in combination MDP. 
Contrarily, I found an increase of TNF-α, CXCL-1 and IL-6 release after stimulation with 
MDP plus Pam3CSK4 similar to the findings of Netea et al. (2005) concerning IL-10 and 
TNF-α. An increase of TNF-α, CXCL-1 and IL-6 release could also be found after co-
stimulating with MDP plus LPS and in case of IL-6 and TNF-α for poly(I:C) plus MDP. In 
the present study, cells showed the highest release of chemo- and cytokines after co-
stimulation with MDP and TLR agonists as shown in Figure 3.6, Figure 3.7 and Figure 3.8. 
While the release of TNF-α and IL-6 were enhanced after the combined stimulation with 
MDP and Pam3CSK4 (TLR1/2 agonist), poly(I:C) (TLR3 agonist) and LPS (TLR4 agonist), 
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the level of CXCL1 increased significantly after simultaneous stimulation with MDP and LPS 
or Pam3CSK4, whereas the addition of MDP to CpG (TLR9 agonist) did not increase chemo- 
or cytokine release.  Although cells stimulated with CpG at submaximum concentration alone 
or in combination with 

0.1g ml and 

10g ml MDP failed to elicit significant amounts of 
the chemo- and cytokines measured, microglial cells previously stimulated with CpG ingested 
significant higher amounts of bacteria. This leads to the question whether this stimulation 
caused the release of chemo- and cytokines not measured in this work. Co-stimulation of 
microglial cells with the Nod2 ligand MDP and TLR agonists showed an increase of bacterial 
uptake compared to stimulation with the TLR agonists or MDP alone, especially when 
bacteria were co-incubated for 

90min . Whereas the addition of submaximum or maximum 
concentration of MDP to cells stimulated with the different TLR agonists at maximum 
concentration did not enhance phagocytosis after 

30min  of challenge with E. coli K1, 
bacterial ingestion was significantly higher after 

90min  of challenge. These results indicated 
that there is a crosstalk between NOD2 and TLR systems, which may need a certain time to 
start signal cascades that result in an increase of bacterial uptake. This could explain the lower 
number of bacterial uptake after 

30min  of exposure to E. coli K1. In accordance to these 
cross-talks, in case of a nasopharyngeal infection with encapsulated Haemophilus influenzae 
TLR and NOD systems were simultaneous needed to fight effectively against the pathogen; 
furthermore the absence of one system resulted in a prolonged infection (Zola et al. 2008). 
This finding supports the results of my experiments indicating benefit from both systems, 
although one has to consider that Zola et al. (2008) focused on stimulation of the NOD1 
system.  
One important point to take into account is that only microglial cells from newborn 
mice were used. We do not know whether microglia cells from old mice have similar 
mechanisms and are capable of ingesting/killing the same number of bacteria. 
Immunocompromised patients including the elderly are at higher risk of suffering infections 
than immunocompetent people. Old people show an impaired immune system. One of the 
questions that arose after the observations of this thesis was to study how MDP alone and in 
combination influenced microglial responses in microglia from old mice. Therefore, further 
experiments were performed with microglia from adult mice (49 days, P49) and parts of these 
data are published together with main parts of the present work (Ribes et al. 2012). The next 
step would be to transfer the findings of the current work to human cells, for which further 
experiments would be necessary. Concentrations of endotoxins, like LPS, found in patients 
suffering from sepsis were described as mlg0001,0   (Shenep et al. 1988, van Deventer et al. 
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1988) which is the submaximum concentrations I used to stimulate microglia before E. coli 
K1 challenge and could represent physiological concentrations.    
  Beran et al. (2011) described an upregulation of TLR2 expression when the human 
organism was challenged with low concentrations of E. coli, whereas a slighter increase of 
TLR2 and an inhibition of TLR4 expression were measured with higher concentrations of E. 
coli. Contrary results were found when cells were exposed to Gram-positive bacteria (Beran 
et al. 2011). On the other hand, mutations causing a loss of function of TLR4 predisposed to 
Gram-negative sepsis, whereas the remaining immune system stays intact (Poltorak et al. 
1998). This generates the question whether the concentration of E. coli K1 chosen for my 
experimental settings represents an “adequate” level. Furthermore the impression occurs that 
microglia express lower numbers of receptors to prevent the immune system from an 
overreaction, before this would lead to further damages or can even adapt to modulate 
immunological consequences (Beran et al. 2011, Hanisch and Kettenmann 2007).  
MDP is known as adjuvant inducing antigen-specific T and B cell responses, delayed-
type hypersensitivity as well as antibody production (Takada and Kotani 1995). Mašek et al. 
(2011) described MDP as one component of an experimental proteoliposome-based vaccine 
formulation against Candida species, since important immune responses were induced 
without toxic side effects. Similarly, administration of biodegradable microparticles 
comprising MDP with bacterial DNA from Propionibacterium acnes (MIS416) resulted in a 
nontoxic Th1 cellular adjuvant with desirable immunostimulatory properties in mice and 
rabbits (Girvan et al. 2011). The synergism of the NOD and the TLR systems may help to 
develop strategies for vaccination and immunotherapy to protect the CNS against invading 
pathogens, especially in immunocompromised patients with a poor local defense. The risk of 
neuronal injury or further progress of selfsame, in acute (Iliev et al. 2004) and chronic CNS 
ailments with a phlogistic component including neurodegenerative diseases (Perry et al. 2007; 
Cunningham et al. 2009) rises with prolonged microglial activation. The aim of future 
experiments is to find a substance which enhances the microglial potential to protect the CNS 
against invading pathogens (e.g. via phagocytosis/clearance) without the consecutive increase 
of damage to dendrites, neuronal somata, or axons.
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5 Summary of conclusions 
The aim of the current work was to study whether murine microglial cells stimulated with 
either the Nod2 ligand MDP or the viral TLR3 agonist poly(I:C) phagocytosed and thereafter 
were enabled to kill higher numbers of E. coli K1 than unstimulated cells. Furthermore, a 
possible synergism between the Nod and TLR systems in terms of release of nitrit and chemo-
/cytokines, phagocytosis and intracellular killing was investigated.  
Meningitis, meningoencephalitis and sepsis are still severe diseases causing many 
victims, especially immunocompromised people, all over the world. Among many pathogens, 
E. coli is the leading cause of Gram-negative neonatal bacterial sepsis and meningitis. 
Patients suffering from those illnesses have severe limitations concerning their well-being, 
fitness and mind. Many of the mentioned problems do not derive directly from invading 
bacteria but from the host response against pathogen invasion. For example, an increasing 
production of chemo- and cytokines induced by compounds released upon bacterial lysis.  
The host response which usually prevents the body from the spread of invading bacteria and 
induces efficient pathways to eliminate the pathogen can become harmful for the organism 
itself. This could be the case, if the organism produces high amounts of mediators resulting in 
an overreaction which consecutive leads to a dysregulation of homoeostasis. Fever or major 
decrease of body temperature might lead to a loss of function of pivotal enzymes. 
Furthermore, blood vessels can dilate resulting in a decrease of blood pressure. It is clear then, 
why it is so important to develop strategies to help the organism to cope with pathogen 
invasion. In the best case scenario the pathogen could be eliminated before the organism had 
triggered signaling pathways and caused a maximum alert of the immune system which 
would lead, in worst case, to a lethal ending. In case of the brain, this part is taken over by 
microglial cells. 
  The release of chemo- and cytokines by murine microglial cells pre-stimulated with 
MDP and/or TLR agonist were measured. These data indicated that murine microglial cells 
can be stimulated by MDP alone, as well as in combinations with TLR agonists, whereupon 
the co-stimulation of MDP and TLR agonists led to the highest amounts of chemo- and 
cytokine release. On the one hand, these measurements indicated that stimulation of microglia 
was successful. On the other hand, MDP and poly(I:C) and CpG could be considered as 
stimuli which enable cells to ingest more bacteria without a strong reaction of the immune 
system.  
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In the current work, I was able to demonstrate for the first time that a stimulation with 
the Nod2 ligand MDP as well as the viral TLR3 agonist poly(I:C) not only enables murine 
microglia to phagocytose significantly higher numbers of pathogenic E. coli K1 bacteria but 
also enhances intracellular bacterial killing compared to unstimulated cells. However, the 
potency of microglial responses elicited by MDP and poly(I:C) was not as strong as the ones 
achieved by agonists of the TLR system recognizing PAMPs from bacterial origin (TLR1/2, 
TLR4 and TLR9). Furthermore, I could demonstrate that a crosstalk between Nod2 and TLR 
systems can enhance the phagocytosis and the intracellular killing of a pathogenic E. coli K1 
strain. The synergism of the NOD2 and the TLR systems may help to develop strategies for 
vaccination and immunotherapy to protect the organism against invading pathogens, 
especially in immunocompromised patients. 
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